About CureVac
CureVac is a company based in Tubingen (Germany) founded in 2000 by Florian Von Der Mulbe was acquired by BioNTech in June 2025.. CureVac has raised $975.35 million across 15 funding rounds from investors including BioNTech, Gates Foundation and Baillie Gifford. The company has 983 employees as of December 31, 2024. CureVac has completed 1 acquisition, including Frame Therapeutics. CureVac offers products and services including mRNA Technology Platform and mRNA COVID-19 Vaccine. CureVac operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BridgeBio, BeiGene and Advanced Accelerator Applications, among others.
- Headquarter Tubingen, Germany
- Employees 983 as on 31 Dec, 2024
- Founders Florian Von Der Mulbe
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Curevac N.V.
-
Annual Revenue
$578.9 M896.07as on Dec 31, 2024
-
Net Profit
$175.44 M162.37as on Dec 31, 2024
-
EBITDA
$243.15 M188.28as on Dec 31, 2024
-
Total Equity Funding
$975.35 M (USD)
in 15 rounds
-
Latest Funding Round
$299 M (USD), Grant
Sep 15, 2020
-
Investors
BioNTech
& 14 more
-
Employee Count
983
as on Dec 31, 2024
- Investments & Acquisitions
-
Acquired by
BioNTech
(Jun 12, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of CureVac
CureVac is a publicly listed company on the NASDAQ with ticker symbol CVAC in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of CureVac
CureVac offers a comprehensive portfolio of products and services, including mRNA Technology Platform and mRNA COVID-19 Vaccine. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Platform for developing mRNA-based medicines and vaccines.
Program focused on mRNA vaccines for COVID-19 prevention.
Unlock access to complete
Unlock access to complete
Funding Insights of CureVac
CureVac has successfully raised a total of $975.35M across 15 strategic funding rounds. The most recent funding activity was a Grant round of $299 million completed in September 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 15
- Last Round Grant — $299.0M
-
First Round
First Round
(01 Jun 2003)
- Investors Count 14
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2020 | Amount | Grant - CureVac | Valuation |
investors |
|
| Jul, 2020 | Amount | Series F - CureVac | Valuation | Qatar Investment Authority |
|
| Jul, 2020 | Amount | Series F - CureVac | Valuation | GSK |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in CureVac
CureVac has secured backing from 15 investors, including institutional and venture fund investors. Prominent investors backing the company include BioNTech, Gates Foundation and Baillie Gifford. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare investments are targeted by this private equity firm.
|
Founded Year | Domain | Location | |
|
Investments are made in life and health sciences companies.
|
Founded Year | Domain | Location | |
|
Finance and advisory services for infrastructure projects are provided.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by CureVac
CureVac has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Frame Therapeutics. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Immunotherapies and personalized vaccines for cancer are developed.
|
2018 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - CureVac
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Curevac Comparisons
Competitors of CureVac
CureVac operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BridgeBio, BeiGene and Advanced Accelerator Applications, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Curevac
Frequently Asked Questions about CureVac
When was CureVac founded?
CureVac was founded in 2000 and raised its 1st funding round 3 years after it was founded.
Where is CureVac located?
CureVac is headquartered in Tubingen, Germany. It is registered at Tubingen, Baden-wurttemberg, Germany.
Is CureVac a funded company?
CureVac is a funded company, having raised a total of $975.35M across 15 funding rounds to date. The company's 1st funding round was a Series F of $171M, raised on Jun 01, 2003.
How many employees does CureVac have?
As of Dec 31, 2024, the latest employee count at CureVac is 983.
What is the annual revenue of CureVac?
Annual revenue of CureVac is $578.9M as on Dec 31, 2024.
What does CureVac do?
CureVac was established in 2000 in Tubingen, Germany, within the biotechnology sector. mRNA technologies are employed to create therapeutics targeting cancer and infectious diseases. RNAntibody platforms are used to produce functional antibodies and proteins from mRNA. Key investigational assets include CV9104, a vaccine for prostate cancer that activates immune responses, CV8102 for cutaneous melanoma, and CV9202 for non-small cell lung cancer. Focus remains on immunotherapy advancements across Europe.
Who are the top competitors of CureVac?
CureVac's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
What products or services does CureVac offer?
CureVac offers mRNA Technology Platform and mRNA COVID-19 Vaccine.
Is CureVac publicly traded?
Yes, CureVac is publicly traded on NASDAQ under the ticker symbol CVAC.
How many acquisitions has CureVac made?
CureVac has made 1 acquisition, including Frame Therapeutics.
Who are CureVac's investors?
CureVac has 15 investors. Key investors include BioNTech, Gates Foundation, Baillie Gifford, European Investment Bank, and GSK.
What is CureVac's ticker symbol?
The ticker symbol of CureVac is CVAC on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.